# Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer

> **NCT00045032** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 5099 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Herceptin
- **DRUG:** Herceptin

## Key facts

- **NCT ID:** NCT00045032
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2005-03
- **Final completion:** 2015-06
- **Target enrollment:** 5099 (ACTUAL)
- **Last updated:** 2017-04-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00045032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00045032, "Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00045032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*